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Aim: The aim of this study is to compare the safety and durability of Sirolimus-eluting stent (SES) and Paclitaxel-eluting stent (PES) on the outcome 
of patients with unprotected left main coronary arteries (LMT). 
Methods: A prospective analysis of 448 patients with LMT stenosis (248 SES and 200 PES) in six high volume Asian centers after successful 
stenting in LMT was performed. Lesion location of LMT was ostial 38 cases (8.5%), mid shaft 56 cases (12.5%) and distal 354 cases (79.0%). 
Complete clinical follow-up to 4 years is being analyzed for 448 patients. 
Results: The baseline clinical characteristics between 2 groups were similar. Angiographic and clinical success were achieved in all patients 
without any major complication. At 4 years overall cardiac events of SES (16.5%) were lower than PES (25.5%) (p=0.018). See figure for clinical 
results.
Conclusion: The use of SES and PES in patients with LMT was safe and feasible with low acute complication and low incidence 
of restenosis. SES showed lesser incidence of cardiac events (death, myocardial infarction, CABG and PCI compared with PES).
